The China Banking and Insurance Regulatory Commission plans to introduce supporting policies to promote commercial insurance innovation.

The China Insurance Regulatory Commission is planning to introduce supporting policies to promote the landing of commercial insurance innovative drugs, aiming to alleviate the pressure of basic medical insurance on the payment of innovative drugs and expand commercialization channels for enterprises. The commercial insurance innovative drug catalog has been released for nearly a month, and how to implement it has attracted much attention from all parties. Provinces have successively started the declaration of information for commercial insurance innovative drugs, and they have been included in Hubei's Huangshi, Yichang, Shenzhen, and Ningbo's 2026 people's livelihood insurance. The China Banking and Insurance Regulatory Commission also plans to release relevant policies in January 2026, involving adjustments to the catalog of millions of medical insurance, focusing on drugs for which previous insurers did not have sufficient data on incidence rates, disease progression, etc., and are currently in the stage of soliciting opinions in a small scale.